COVID-19 Coronavirus

As the leader in developing clinical guidelines and standards in addiction medicine, we take our responsibility very seriously. We realize that many providers and programs are trying to mitigate circumstances related to COVID-19. We have convened the ASAM Caring for Patients During the COVID-19 (CPDC) Task Force. The Task Force includes a national panel of experts that are recognized in the field of addiction medicine. They are rapidly producing comprehensive resources tailored to addiction medicine treatment within the context of the COVID-19 pandemic.

To address the urgency of the situation, we will provide these resources in real-time as we have them developed. Physicians should use their personal and professional judgment in interpreting these guidances and applying them to the particular circumstances of their individual patients and practice arrangements.

These materials are provided for educational and informational purposes only. This guidance is not intended to provide legal or medical advice and should not be relied upon as such.

Please read our content disclaimer.

covid-webinar

Free CME Webinar

This webinar recording provides an overview of the resources available to help you adjust your practices during this challenging time. (1 hour)

RESOURCE AREAS

Access to Buprenorphine

Guidance to ambulatory addiction treatment providers, including those working in primary care, and programs as they strive to ensure that patients continue to have appropriate access to buprenorphine.

Infection Mitigation: Outpatient Settings

This provides guidance to outpatient addiction treatment providers and programs when developing infection control procedures to address the COVID-19 pandemic.

Infection Mitigation: Residential Treatment Facilities

Guidance to residential addiction treatment programs (ASAM Levels 3.1, 3.3, 3.5 and 3.7), supporting the development of infection control and mitigation procedures to address the COVID-19 pandemic.

Adjusting Drug Testing Protocols

Balancing the utility of having the data from a urine drug test against the risk of COVID-19 virus exposure to patients, laboratory staff, and clinic staff/providers.

National & State Guidance

This webpage contains news, guidance and resources from around the country regarding addiction treatment in the wake of COVID-19.

Telehealth Access for Addiction Treatment

Regulatory Overview and General Practice Considerations

Support Group Participation

A guide for addiction treatment providers and programs working to treat patients with substance use disorders safely and effectively during the COVID-19 pandemic.

Coming soon:

Access to Methadone

American Society of Addiction Medicine

COVID-19 - Resources

RESOURCE AREAS

Access to Buprenorphine

Infection Mitigation: Residential Treatment Facilities

Adjusting Drug Testing Protocols

Coming soon:

Patients

About COVID-19 Taskforce Members

Feedback?

American Society of Addiction Medicine